Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sze Ting Lee, Hong Ji, David W. Greening, Robert W. H. Speirs, Angela Rigopoulos, Vinochani Pillay, Carmel Murone, Angela Vitali, Kai Stühler, Terrance G. Johns, Georgia A. Corner, John M. Mariadason, Richard J. Simpson & Andrew M. Scott. (2013) Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts. Growth Factors 31:5, pages 154-164.
Read now
Read now
Shiran Shapira, Victoria Lisiansky, Nadir Arber & Sarah Kraus. (2010) Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins. Expert Opinion on Investigational Drugs 19:sup1, pages S67-S77.
Read now
Read now
David Gallagher & Nancy Kemeny. (2009) Treatment of patients with colorectal cancer: emphasis on liver metastases. Expert Opinion on Pharmacotherapy 10:1, pages 109-124.
Read now
Read now
Timothy E. Adams, Eva J. Koziolek, Peter H. Hoyne, John D. Bentley, Louis Lu, George Lovrecz, Colin W. Ward, F. T. Lee, Andrew M. Scott, Andrew D. Nash, Julie Rothacker, Edouard C. Nice, Antony W. Burgess, Terrance G. Johns, Timothy E. Adams, Eva J. Koziolek, Peter H. Hoyne, John D. Bentley, Louis Lu, George Lovrecz, Colin W. Ward, F. T. Lee, Andrew M. Scott, Andrew D. Nash, Julie Rothacker, Edouard C. Nice, Antony W. Burgess & Terrance G. Johns. (2009) A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. Growth Factors 27:3, pages 141-154.
Read now
Read now
Articles from other publishers (42)
Vaishali Gupta, Taha Bharmal, Vineeta Dixit, Naveen Kumar Vishvakarma, Atul Kumar Tiwari, Dhananjay Shukla & Shirish Shukla. 2021. Colon Cancer Diagnosis and Therapy. Colon Cancer Diagnosis and Therapy
219
238
.
Barbara Carreira, Rita C. Acúrcio, Ana I. Matos, Carina Peres, Sabina Pozzi, Daniella Vaskovich‐Koubi, Ron Kleiner, Mariana Bento, Ronit Satchi‐Fainaro & Helena F. Florindo. (2020) Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. Advanced Therapeutics 4:1, pages 2000147.
Crossref
Crossref
Yi-Ting Chen, Shu-Chuan Tsao, Hung-Pei Tsai, Jaw-Yuan Wang & Chee-Yin Chai. (2016) Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy. Journal of Clinical Pathology 69:11, pages 974-978.
Crossref
Crossref
E. Allen Sickmier, Robert J. M. Kurzeja, Klaus Michelsen, Mukta Vazir, Evelyn Yang & Andrew S. Tasker. (2016) The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance. PLOS ONE 11:9, pages e0163366.
Crossref
Crossref
Liping Li, Tingmei Duan, Xin Wang, Ru-Hua Zhang, Meifang Zhang, Suihai Wang, Fen Wang, Yuanzhong Wu, Haojie Huang & Tiebang Kang. (2016) KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway. Scientific Reports 6:1.
Crossref
Crossref
Yi-Ting Chen, Shu-Chuan Tsao, Shyng-Shiou F. Yuan, Hung-Pei Tsai & Chee-Yin Chai. (2015) Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker. Pathology & Oncology Research 21:4, pages 1201-1208.
Crossref
Crossref
Siu Ling Leung, Zhengbao Zha, Celine Cohn, Zhifei Dai & Xiaoyi Wu. (2014) Anti-EGFR antibody conjugated organic–inorganic hybrid lipid nanovesicles selectively target tumor cells. Colloids and Surfaces B: Biointerfaces 121, pages 141-149.
Crossref
Crossref
Jenia Jenab-Wolcott & Bruce Giantonio. (2013) The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer. Current Colorectal Cancer Reports 9:3, pages 230-241.
Crossref
Crossref
Edward Chu. (2012) An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer. Clinical Colorectal Cancer 11:1, pages 1-13.
Crossref
Crossref
Noga Kozer, Marcus P. Kelly, Suzanne Orchard, Antony W. Burgess, Andrew M. Scott & Andrew H. A. Clayton. (2011) Differential and Synergistic Effects of Epidermal Growth Factor Receptor Antibodies on Unliganded ErbB Dimers and Oligomers. Biochemistry 50:18, pages 3581-3590.
Crossref
Crossref
Yicheng Wu, Maoquan Chu, Bizhi Shi & Zonghai Li. (2010) A Novel Magneto-fluorescent Nano-bioprobe for Cancer Cell Targeting, Imaging and Collection. Applied Biochemistry and Biotechnology 163:7, pages 813-825.
Crossref
Crossref
T. Doi, M. Tahara, T. Yoshino, K. Yamazaki, T. Tamura, Y. Yamada, B.-B. Yang, K. S. Oliner, S. Otani & D. Asahi. (2010) Tumor KRAS Status Predicts Responsiveness to Panitumumab in Japanese Patients with Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology 41:2, pages 210-216.
Crossref
Crossref
Robert Königsberg, Wolfgang Hulla, Martin Klimpfinger, Angelika Reiner-Concin, Tanja Steininger, Wilfried Büchler, Robert Terkola & Christian Dittrich. (2011) Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients. Oncology 81:5-6, pages 359-364.
Crossref
Crossref
Lin Yang, Hua Jiang, Bizhi Shi, Huamao Wang, Jinjun Li, Hai Wang, Ming Yao & Zonghai Li. (2010) Identification and characterization of Ch806 mimotopes. Cancer Immunology, Immunotherapy 59:10, pages 1481-1487.
Crossref
Crossref
Jan Ouwerkerk & Christine Boers-Doets. (2010) Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. European Journal of Oncology Nursing 14:4, pages 337-349.
Crossref
Crossref
Ralf Lutterbuese, Tobias Raum, Roman Kischel, Patrick Hoffmann, Susanne Mangold, Benno Rattel, Matthias Friedrich, Oliver Thomas, Grit Lorenczewski, Doris Rau, Evelyne Schaller, Ines Herrmann, Andreas Wolf, Thomas Urbig, Patrick A. Baeuerle & Peter Kufer. (2010) T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proceedings of the National Academy of Sciences 107:28, pages 12605-12610.
Crossref
Crossref
Wolfram Brugger. (2018) Successful Treatment with the Fully Human Antibody Panitumumab after a Severe Infusion Reaction with Cetuximab. Tumori Journal 96:3, pages 473-477.
Crossref
Crossref
Michael C. FlickingerKristina W. Thiel & Graham Carpenter. 2009. Encyclopedia of Industrial Biotechnology. Encyclopedia of Industrial Biotechnology.
Issa J. Dahabreh, Helena Linardou, Fotios Siannis, Paris Kosmidis, Dimitrios Bafaloukos & Samuel Murray. (2010)
Somatic
EGFR
Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
. Clinical Cancer Research 16:1, pages 291-303.
Crossref
Crossref
Yong Li. 2010. Systems Biology for Signaling Networks. Systems Biology for Signaling Networks
491
504
.
Erin E. Mancl, Jill M. Kolesar & Lee C. Vermeulen. (2009)
Clinical and economic value of screening for
Kras
mutations as predictors of response to epidermal growth factor receptor inhibitors
. American Journal of Health-System Pharmacy 66:23, pages 2105-2112.
Crossref
Crossref
Zhao Jing, Ling Gong, Cong-Ying Xie, Li Zhang, Hua-Fang Su, Xia Deng & Shi-Xiu Wu. (2009) Reverse resistance to radiation in KYSE-150R esophageal carcinoma cell after epidermal growth factor receptor signal pathway inhibition by cetuximab. Radiotherapy and Oncology 93:3, pages 468-473.
Crossref
Crossref
James M. Cleary, Kenneth T. Tanabe, Gregory Y. Lauwers & Andrew X. Zhu. (2009) Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver. The Oncologist 14:11, pages 1095-1105.
Crossref
Crossref
Lorena Leal Canosa, María José Fuente González & Miquel Ribera Pibernat. (2009) Efectos secundarios cutáneos de los fármacos antineoplásicos (II): inhibidores de cinasas y anticuerpos monoclonales. Piel 24:8, pages 427-439.
Crossref
Crossref
Helena Linardou, Issa J. Dahabreh, Dimitrios Bafaloukos, Paris Kosmidis & Samuel Murray. (2009) Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Reviews Clinical Oncology 6:6, pages 352-366.
Crossref
Crossref
Yvonne Y. Ho & Wai‐Kit Lee. (2008) Metastasis to the breast from an adenocarcinoma of the colon. Journal of Clinical Ultrasound 37:4, pages 239-241.
Crossref
Crossref
Anthony J. Mutsaers, Giulio Francia, Shan Man, Christina R. Lee, John M.L. Ebos, Yan Wu, Larry Witte, Scott Berry, Malcolm Moore & Robert S. Kerbel. (2009) Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent. Clinical Cancer Research 15:7, pages 2397-2405.
Crossref
Crossref
Silke Lankiewicz, Silke Zimmermann, Christiane Hollmann, Tina Hillemann & Tim F. Greten. (2008) Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Molecular Oncology 2:4, pages 349-355.
Crossref
Crossref
Laura Q. M. Chow, Daniel L. Gustafson, Cindy L. O’Bryant, Lia Gore, Michele Basche, Scott N. Holden, Mark C. Morrow, Stacy Grolnic, Brian R. Creese, Kaye L. Roberts, Kat Davis, Russell Addison & S. Gail Eckhardt. (2008) A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology 63:1, pages 65-74.
Crossref
Crossref
Jennifer H.E. Baker, Jeffrey Lam, Alaistair H. Kyle, Jonathan Sy, Thomas Oliver, Steven J. Co, Wieslawa H. Dragowska, Euan Ramsay, Malathi Anantha, Thomas J. Ruth, Michael J. Adam, Andrew Yung, Piotr Kozlowski, Andrew I. Minchinton, Sylvia S.W. Ng, Marcel B. Bally & Donald T.T. Yapp. (2008) Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin. Clinical Cancer Research 14:22, pages 7260-7271.
Crossref
Crossref
Helena Linardou, Issa J Dahabreh, Dimitra Kanaloupiti, Fotios Siannis, Dimitrios Bafaloukos, Paris Kosmidis, Christos A Papadimitriou & Samuel Murray. (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. The Lancet Oncology 9:10, pages 962-972.
Crossref
Crossref
Robert M. Sharkey & David M. Goldenberg. (2008) Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Advanced Drug Delivery Reviews 60:12, pages 1407-1420.
Crossref
Crossref
Xuan Liu, William K. K. Wu, Le Yu, Zhi J. Li, Joseph J. Y. Sung, Shu T. Zhang & Chi H. Cho. (2008) Epidermal Growth Factor-Induced Esophageal Cancer Cell Proliferation Requires Transactivation of β-Adrenoceptors. Journal of Pharmacology and Experimental Therapeutics 326:1, pages 69-75.
Crossref
Crossref
Yong Li, Pankaj Agarwal & Dilip Rajagopalan. (2008) A global pathway crosstalk network. Bioinformatics 24:12, pages 1442-1447.
Crossref
Crossref
Jun-ichi Okano, Takakazu Nagahara, Kazuya Matsumoto & Yoshikazu Murawaki. (2008) Caffeine Inhibits the Proliferation of Liver Cancer Cells and Activates the MEK/ERK/EGFR Signalling Pathway. Basic & Clinical Pharmacology & Toxicology 102:6, pages 543-551.
Crossref
Crossref
Stephen J. Fuller, Kenga Sivarajah & Peter H. Sugden. (2008) ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. Journal of Molecular and Cellular Cardiology 44:5, pages 831-854.
Crossref
Crossref
Hamed Kargozaran, Morton Kahlenberg & Vijay P. Khatri. (2008) The Implications of Colorectal Cancer Molecular Biology in Clinical Practice. Surgical Oncology Clinics of North America 17:2, pages 341-355.
Crossref
Crossref
Philipp C. Manegold, Georg Lurje, Alexandra Pohl, Yan Ning, Wu Zhang & Heinz-Josef Lenz. (2008) Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology 3:2, pages 87-99.
Crossref
Crossref
Anke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari, Roxanne Cofiell, Susan J. Faas & Katherine S. Bowdish. (2008) Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy. The Journal of Immunology 180:2, pages 699-705.
Crossref
Crossref
Lorianne S. Turner. 2008. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
3
.
Jürgen Eberle, Bahtier M. Kurbanov, Amir M. Hossini, Uwe Trefzer & Lothar F. Fecker. (2007) Overcoming apoptosis deficiency of melanoma—Hope for new therapeutic approaches. Drug Resistance Updates 10:6, pages 218-234.
Crossref
Crossref
Sabine Tejpar. (2007) The use of molecular markers in the diagnosis and treatment of colorectal cancer. Best Practice & Research Clinical Gastroenterology 21:6, pages 1071-1087.
Crossref
Crossref